Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) Return on Capital Employed (2021 - 2025)

Historic Return on Capital Employed for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Q3 2025 value amounting to 0.55%.

  • Rhythm Pharmaceuticals' Return on Capital Employed rose 4100.0% to 0.55% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.55%, marking a year-over-year increase of 4100.0%. This contributed to the annual value of 1.07% for FY2024, which is 4700.0% down from last year.
  • Per Rhythm Pharmaceuticals' latest filing, its Return on Capital Employed stood at 0.55% for Q3 2025, which was up 4100.0% from 0.71% recorded in Q2 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Return on Capital Employed peaked at 0.37% during Q2 2021, and registered a low of 1.12% during Q1 2024.
  • Its 5-year average for Return on Capital Employed is 0.7%, with a median of 0.64% in 2023.
  • As far as peak fluctuations go, Rhythm Pharmaceuticals' Return on Capital Employed plummeted by -5600bps in 2024, and later skyrocketed by 5000bps in 2025.
  • Rhythm Pharmaceuticals' Return on Capital Employed (Quarter) stood at 0.57% in 2021, then rose by 9bps to 0.52% in 2022, then decreased by -24bps to 0.64% in 2023, then crashed by -58bps to 1.01% in 2024, then skyrocketed by 45bps to 0.55% in 2025.
  • Its Return on Capital Employed was 0.55% in Q3 2025, compared to 0.71% in Q2 2025 and 0.62% in Q1 2025.